MARKET

AVEO

AVEO

Aveo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.01
+0.26
+3.85%
After Hours: 7.00 -0.01 -0.14% 17:37 05/17 EDT
OPEN
6.82
PREV CLOSE
6.75
HIGH
7.18
LOW
6.71
VOLUME
512.24K
TURNOVER
--
52 WEEK HIGH
18.24
52 WEEK LOW
4.070
MARKET CAP
240.87M
P/E (TTM)
-3.5224
1D
5D
1M
3M
1Y
5Y
Analysts Conflicted on These Healthcare Names: AVEO Pharma (AVEO) and Inovio Pharmaceuticals (INO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on AVEO Pharma (AVEO) and Inovio Pharmaceuticals (INO). AVEO Pharma (AVEO)
SmarterAnalyst · 6d ago
8-K: AVEO PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- false 0001325879 0001325879 2021-05-10 2021-05-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
BRIEF-Aveo Oncology Posts Q1 Loss Per Share Of $0.81
reuters.com · 05/10 22:17
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 05/10 22:15
AVEO Pharmaceuticals Q1 EPS $(0.81) Misses $(0.55) Estimate, Sales $1.92M Beat $1.01M Estimate
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.55) by 47.27 percent. This is a 55.77 percent decrease over losses of $(0.52) per share
Benzinga · 05/10 21:01
10-Q: AVEO PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion...
Edgar Online - (EDG = 10Q, 10K) · 05/10 20:38
AVEO Pharmaceuticals EPS misses by $0.26, beats on revenue
AVEO Pharmaceuticals (AVEO): Q1 GAAP EPS of -$0.81 misses by $0.26.Revenue of $1.92M (+146.2% Y/Y) beats by $0.91M.AVEO believes that its $121.4 million in cash and cash equivalents as of
Seekingalpha · 05/10 20:17
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
--- FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 -
BusinessWire · 05/10 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVEO. Analyze the recent business situations of Aveo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVEO stock price target is 22.00 with a high estimate of 27.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 11.36M
% Owned: 33.05%
Shares Outstanding: 34.36M
TypeInstitutionsShares
Increased
13
336.73K
New
8
400.55K
Decreased
7
1.28M
Sold Out
7
121.80K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
President/Chief Executive Officer/Director
Michael Bailey
Chief Financial Officer
Erick Lucera
Other
Mike Ferraresso
Other
Michael Needle
Lead Director/Independent Director
Kenneth Bate
Director
Kevin Cullen
Director
Corinne Epperly
Independent Director
Anthony Evnin
Independent Director
Gregory Mayes
Independent Director
Scarlett Spring
Independent Director
Robert Young
No Data
About AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Webull offers kinds of AVEO Pharmaceuticals, Inc. stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVEO stock methods without spending real money on the virtual paper trading platform.